Search the Newsreel

IMDX Looks 284.7% Overvalued on GF Value™

Insight Molecular Diagnostics Inc (IMDX) is considered 284.7% overvalued based on its GF Value™ despite optimism around future FDA authorization for its GraftAssureDx test and expanded Medicare reimbursement. The company reported a Q2 adjusted EBITDA loss and an upward revision of its cash burn …

Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA authorization later this year

Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q2 2026 MANAGEMENT VIEW * "It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx" (President, CEO & Director Joshua Riggs), adding, "We continue to target receipt …

Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results

* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates

Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …

Insight Molecular Diagnostics: Q2 Earnings Snapshot

The provided content is not an article but rather a privacy notice or a placeholder. It does not contain any information about Insight Molecular Diagnostics or its Q2 earnings. Therefore, no meaningful summary can be generated.

Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com

This article announces the filing of a Form 8K by Insight Molecular Diagnostics Inc. on August 10. The filing is a standard regulatory announcement, and the article provides no further details beyond the company name and filing date. It appears to be a placeholder …

Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash

Insight Molecular Diagnostics (IMDX) reported a steep revenue drop in Q2 2026, with net revenue down sharply to $239,000 from $518,000 in the prior year, and a net loss of $11.3 million. Despite the revenue decline and increased operating expenses, the company bolstered its …

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

Insight Molecular Diagnostics Inc. (IMDX) reported its Q2 2026 results and provided an update on the FDA review of its GraftAssureDx product. The company is progressing with the FDA, expecting marketing authorization soon, and highlighted favorable Medicare reimbursement policy changes. IMDX also shared clinical …

JPMorgan Chase & Co. Increases Molson Coors Beverage (NYSE:TAP) Price Target to $42.00

Molinos Agro S.A. presenta sus resultados del primer trimestre finalizado el 30 de junio de 2026

Molinos Juan Semino S.A. presenta sus resultados anuales correspondientes al ejercicio cerrado el 31 de mayo de 2026

Tilray to cease brewing at Terrapin site in US

Tilray Brands will stop brewing beer at its Terrapin facility in Athens, Georgia, moving production to other breweries within its network as part of a broader optimization strategy. The taproom, warehouse, and repack operations in Athens will remain open, and Terrapin will continue as …

IMDX Stock Price and Chart — NASDAQ:IMDX

This article provides an overview of Insight Molecular Diagnostics Inc. (IMDX) stock, including its current price, market capitalization, key financial stats, and performance over various periods. It also highlights analyst opinions, future earnings expectations, and company details, noting the FDA review for GraftAssureDx and …

Molina Healthcare, Inc $MOH Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC significantly reduced its stake in Molina Healthcare, Inc ($MOH) by 65.6% in the first quarter, selling 42,387 shares and retaining 22,250 shares valued at $2.97 million. Despite this, institutional investors still own 98.5% of the company, and analysts generally maintain a …

Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Colgate-Palmolive Company (NYSE:CL) Given Average Rating of "Moderate Buy" by Brokerages

Colgate-Palmolive (NYSE:CL) has received a "Moderate Buy" consensus rating from nineteen research firms, with an average 12-month price target of $99.00. The company recently exceeded quarterly earnings expectations, reporting $0.99 per share against a $0.95 consensus, and saw a 4.9% revenue increase year-over-year. Insider …

TAP Q2 Deep Dive: Margin Pressures Persist as Molson Coors Leans on Brand and Portfolio Initiatives

TAP Q2 Deep Dive: Margin Pressures Persist as Molson Coors Leans on Brand and Portfolio Initiatives Beer company Molson Coors (NYSE:TAP) met Wall Street's revenue expectations in Q2 CY2026, but sales fell by 3.3% year on year to $3.10 billion. Its non-GAAP profit of …

Anmol India standalone net profit rises 4.90% in the June 2026 quarter

5 Revealing Analyst Questions From Colgate-Palmolive’s Q2 Earnings Call

5 Revealing Analyst Questions From Colgate-Palmolive's Q2 Earnings Call Colgate-Palmolive's second quarter results were met with a cautious market response, as the company's revenue matched Wall Street's expectations while non-GAAP profit modestly exceeded consensus. Management attributed the quarter's performance to continued strength in emerging …

Molina Healthcare Inc (MOH) Stock Forecasts

Argus has lowered its target price for Molina Healthcare Inc (MOH) to $201.00, with the stock currently trading at $196.45. The report, dated August 05, 2026, focuses on Molina Healthcare's offerings in Medicaid-related solutions for low-income individuals. Users can access the full report and …

MOH5074366 Bond Risk Profile

This article provides a risk profile for the Molina Healthcare, Inc. bond MOH5074366, which is a 3.875% bond maturing on November 15, 2030. It focuses on offering key metrics for credit risk assessment, including the bond's security level, inflation protection, and issuer rating to …

Insight Molecular Diagnostics Q2 2026 Earnings Preview

* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …

Assenagon Asset Management S.A. Has $35.82 Million Holdings in Molina Healthcare, Inc $MOH

Assenagon Asset Management S.A. significantly increased its stake in Molina Healthcare, Inc. (MOH) by 394.1% in the second quarter, now holding 156,632 shares valued at $35.82 million. The company's recent earnings report showed $1.51 EPS and $10.87 billion in revenue, beating estimates, though revenue …

Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX)

What to Know About Colgate-Palmolive Director John Cahill Selling 4,170 Shares for $389,353

Colgate-Palmolive Director John Cahill sold 4,170 shares for approximately $389,353 on August 6, 2026, as part of a routine exercise and sale of stock options. This transaction reduced his direct holdings by 13% but is not seen as an indicator of market timing, with …

Colgate-Palmolive Company (CL) Stock Forecasts

This article provides stock forecasts for Colgate-Palmolive Company (CL), highlighting its strong competitive edge derived from consistent brand investments. According to a Morningstar analyst report from August 3, 2026, Colgate-Palmolive is a leading player in the household and personal care industry, with its oral …

Transcript : Mold-Tek Technologies Limited, Q1 2027 Earnings Call, Aug 06, 2026

Molson Coors (TAP) Stock Rally Faces Margin Pressure And Losses

Molson Coors (TAP) shares recently rallied by 12% over the past month, with Q2 2026 revenue at US$3.10 billion and EPS at US$1.24. Despite efforts in premium and "Beyond Beer" segments, the company faces significant margin pressure, declining net income, and a shift from …

Colgate-Palmolive (NYSE: CL) director exercises options, sells 4,170 shares

Colgate-Palmolive director John T. Cahill exercised stock options for 4,170 shares at $71.56 per share and simultaneously sold these 4,170 shares at a weighted average price of $93.3712 to $93.39 on August 6, 2026. A portion of the proceeds covered the exercise price. After …

3 Consumer Staples Stocks For Steadier Returns If The Economy Stays Soft

Amidst a soft economic outlook with job losses and lagging wage growth, investors are seeking resilient options. This article highlights three consumer staples stocks—Molson Coors Beverage (TAP), C&C Group (LSE:CCR), and RLX Technology (RLX)—that offer potential for steadier returns in such an environment. Each …

Cómo están reaccionando los inversores ante la reafirmación de las previsiones de Colgate-Palmolive (CL) en un contexto de aumento de las ventas y descenso de los beneficios

Wie Investoren auf die Bestätigung der Prognose durch Colgate-Palmolive (CL) angesichts höherer Umsätze und geringerer Gewinne reagieren

How Investors Are Reacting To Colgate-Palmolive (CL) Reaffirming Guidance Amid Higher Sales And Lower Profit

Colgate-Palmolive (CL) reported higher sales but lower net income in Q2 2026 compared to the previous year. Despite softer profitability, the company reaffirmed its full-year 2026 guidance for net sales growth of 2% to 6% and double-digit GAAP EPS growth. This article examines the …

Anmol India Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Anmol India Q1 Results: Net profit rises 4.9% YoY to ₹6.00 crore

4D Molecular Therapeutics Inc (FDMT) Stock News Today

This article provides current stock information for 4D Molecular Therapeutics Inc (FDMT), noting its recent price dip. It states that more news regarding FDMT's earnings, analyst ratings, and key developments will be available soon. The page serves as a hub for investors to track …